tiprankstipranks
Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
US Market
ATAI
Atai Beckley N.V.
RESEARCH TOOLSreports
Want to see ATAI full AI Analyst Report?

Atai Beckley N.V. (ATAI) Stock News & Sentiment

2,158 Followers
Reiterated Buy on Atai Beckley as Robust EMP-01 Phase IIa Data and Solid Cash Position Support $16 Price Target
Premium
Ratings
Reiterated Buy on Atai Beckley as Robust EMP-01 Phase IIa Data and Solid Cash Position Support $16 Price Target
10d ago
ATAI
PBM, CMPS, ATAI: Psychedelic Biotech Stocks Soar after White House Order for Faster FDA Reviews
Premium
Market News
PBM, CMPS, ATAI: Psychedelic Biotech Stocks Soar after White House Order for Faster FDA Reviews
12d ago
PBM
ATAI
Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
Premium
Ratings
Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
16d ago
ATAI
ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
ATAI
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating
Premium
Ratings
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating
1M ago
ATAI
Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price
Premium
Ratings
Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price
2M ago
ATAI
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection
Premium
Ratings
ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection
2M ago
ATAI
More ATAI News >

ATAI News on the Web

Trump Trade: President to sign order on psychedelic used for PTSD
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atai Beckley N.V. (ATAI)
TipRanks News
Bullish
AtaiBeckley price target raised to $16 from $11 at Guggenheim
TipRanks News
Neutral
Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
TipRanks News
Bullish
ATAI Stock Rises on Potential Executive Order for Ibogaine Research
GuruFocus News
Bullish
Trump to sign order on psychedelic used for PTSD, CBS News says
TipRanks News
Bullish
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
TipRanks News
Neutral
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003
Proactive Investors
Bullish

News Score - Last 7 Days

Very Positive
ATAI
Sector Average
Media Buzz
This Week6 articles
Weekly Average4.5 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ATAI’s Media Buzz Sentiment?
6 articles about ATAI were published this week. In an average week, 4.5 articles are published.
    What is ATAI’s weekly average amount of articles?
    In an average week, 4.5 articles about ATAI are published.
      What is ATAI’s News Sentiment?
      100% of articles about ATAI were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week